Sign in
Active, not recruitingPhase 3

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Key facts

Who runs it
GC Biopharma Corp
Where
Aurora, Centennial, Dallas, Fairfax, and Richmond, United StatesSee the 5 sitesAlso in 2 other countries, 3 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
24 people, planned
Started
21 Dec 2020
Expected to end
Nov 2026
Type of study
Interventional
Treatments tested
  • GC5107
Record updated
25 July 2025

Who can take part

Age
2 years to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Subject must be ≥ 2 to < 17 years of age, at the time of signing the informed consent
  • Pediatric subject has a confirmed and documented clinical diagnosis of Primary Humoral Immunodeficiency, including hypogammaglobulinemia or agammaglobulinemia
  • Subject who has received 300 - 900 mg/kg of IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study
  • Subject who has at least 2 documented plasma IgG trough level of ≥ 500 mg/dL at two infusion cycles (21 or 28 days) within 12 months prior to enrollment
  • Subject who is willing to comply with all requirements of the protocol

Who cannot take part

  • Subject who has IgA deficiency and is known to have antibodies to IgA
  • Subject who has participated in another clinical study (other than an IGIV study) within 3 weeks prior to screening
  • Subject who has a history of clinically significant reactions or hypersensitivity to IGIV or other injectable forms of IgG
  • Subject who has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency or isolated IgA deficiency, or who has clinically significant impairment of cellular or innate immunity at the discretion of the Investigator
  • Subject who has received blood products other than human albumin or human immune globulin within 6 months prior to enrollment
  • Subject who has secondary immunodeficiency

Where in United States

Also in 2 other countries, 3 sites

  • Children's Hospital ColoradoAurora, United States
  • Immunoe Health & Research CentersCentennial, United States
  • Allergy Partners of North Texas ResearchDallas, United States
  • Lysosomal and Rare Disorders Research and Treatment Center, IncFairfax, United States
  • Children's Hospital of Richmond at VCURichmond, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).

The group in the trial

  • GC5107Treatment being tested

    Immune Globulin Intravenous (Human), 10% Liquid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Evaluate the Pharmacokinetics and Safety of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
Record updated
25 July 2025